The Joslin Clinical Guideline for Adults with Diabetes is designed to assist primary care physicians and specialists individualize the care of, and set goals for adult, non-pregnant patients with diabetes. This Guideline focuses on the unique needs of the patient with diabetes. It is not intended to replace sound medical judgment or clinical decision-making and may need to be adapted for certain patient care situations where more or less stringent interventions are necessary. The objectives of the Joslin Clinical Diabetes Guidelines are to support clinical practice and to influence clinical behaviors in order to improve clinical outcomes and assure that patient expectations are reasonable and informed. Guidelines are developed and approved through the Clinical Oversight Committee that reports to the Medical Director of Joslin Diabetes Center. The Clinical Guidelines are established after careful review of current evidence, medical literature and sound clinical practice. This Guideline will be reviewed periodically and modified as clinical practice evolves and medical evidence suggests.

Joslin’s Guidelines are evidence-based. In order to allow the user to evaluate the quality of the evidence used to support each standard of care, a modification of the GRADE system has been adopted. The table provided on page 13 describes the categories in which methodological quality and strength of recommendations have been classified. Evidence levels are graded 1A through 2C, as indicated in brackets. Where evidence is not graded, recommendations are made based on the expertise of the Clinical Oversight Committee.

**APPROACH TO CARE**

**Team care:** Diabetes is best managed by a team including medical specialists and diabetes educators. The patient needs to be informed of the roles of the various team members. If access to a team is not possible within the office practice, identify community resources. Clear communication between all providers is critical to ensure patients’ needs are being met.

**Patient centric:** Diabetes is a condition that requires self-management. A collaborative counseling model (where the patient is involved in decisions and goal setting) helps promote behavior change. Whenever appropriate, with the patient’s consent, involve family members and caregivers in medical visits and education.

**Individualized treatment plan:** Develop a treatment plan based on a thorough assessment which includes an understanding of not only the patient’s medical needs, but all the factors that may affect the development of a treatment plan, including social history, race, cultural issues, ethnicity, education needs (including literacy and numeracy), and barriers to care. The plan identifies medical treatment, educational interventions and follow-up. Consider use of a flow sheet to track care parameters and identify areas for intervention.

**Regular medical visits:** The frequency of visits for ongoing care should be individualized, but usually includes at least 2-4 routine visits/year. Special attention should be given to patients who fail to keep scheduled appointments, have frequent hospitalizations or missed days of work/school. Since many factors contribute to patients’ ability to manage their care, the provider should:

- engage patients in identifying and resolving contributing factors or barriers to under-utilization or over-utilization of healthcare services
- consider referral to a diabetes educator (DE), social services or a mental health professional to address possible barriers and/or psychosocial problems
- establish a process of follow-up communication regarding achievement (progress) of the treatment plan, sustaining behaviors and identifying obstacles to care

**A1C**

**Diagnosis:**
An A1C* level of 6.5% or higher on 2 separate days is acceptable for diagnosis of diabetes. [1B]. However, some individuals may have an A1C < 6.5% with diabetes diagnosed by previously established blood glucose criteria. Those with an A1C of 5.7-6.4% are at increased risk for diabetes, and should be treated with lifestyle changes and followed more frequently.

*The A1C should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay.

**Follow-up visits:**
Check the hemoglobin A1C (A1C) 2-4 times a year as part of the scheduled medical visit, with frequency dependent upon revision of the treatment program and the need to reinforce behavior changes. Increase frequency when therapy has changed and/or when glycemic goals are not met. Having the A1C result at the time of the visit can be useful in making timely treatment decisions. [1C]
Goal:
A1C target goal should be individualized for each patient. A goal of < 7% is chosen as a practical level for most patients to avoid the risk of complications. Achieving normal blood glucose is recommended if it can be done practically and safely. [1B]

The goal may be modified based upon presence or absence of microvascular and/or cardiovascular complications, cognitive status and life expectancy. [1A]

Some clinicians may translate patients’ A1C level into their estimated average glucose level (eAG), based upon the work of the A1C Derived Average Glucose Study (ADAG). This is also a valid metric to use in following diabetes treatments.

Joslin’s A1C goal is consistent with that of the ADA. Other expert panels, such as AACE/IDF suggest that the goal of treatment should be ≤ 6.5%.

For patients with longstanding type 2 diabetes with pre-existing CVD, or high CAD risk (diabetes plus 2 or more additional risk factors), consider revising A1C goals to maintain safety. [1B]

Treatment:
If A1C is ≥7% and <8%, or above the individualized goal for 6 or more months:

- Review and clarify the management plan with the patient with attention to:
  - nutrition and meal planning [1B]
  - physical activity [1A]
  - medication administration schedule, technique and practices [1A]
  - self-monitoring blood glucose (SMBG) schedule and technique [1A]
  - treatment of hypoglycemia and hyperglycemia
  - sick day management practices
- Reassess goals and adjust medication as needed. [1A]
- Establish and reinforce individualized glycemic goals with patient.
- Consider referring patient to diabetes educator (DE) for evaluation, diabetes self-management education (DSME) and ongoing consultation. [2A]
- Consider referral to registered dietitian (RD) for medical nutrition therapy (MNT). [2B]
- Schedule follow-up appointment within 3-4 months or more frequently as situation dictates.

If A1C is ≥8%

- Review and clarify the plan as previously noted. [1B]
- Assess for psychosocial stress. [1C]
- Establish and reinforce individualized glycemic goals with the patient.
- Intensify therapy.

- Refer patient to DE for evaluation, DSME and ongoing consultation. Document reason if no referral initiated. [1A]
- Refer patient to RD for MNT. [1B]

If history of severe hypoglycemia or hypoglycemia unawareness (a condition in which the patient is unable to recognize symptoms of hypoglycemia until they become severe):

- assess for changes in daily routine such as decreased food intake or increased activity [1C]
- refer to DE for evaluation, DSME and hypoglycemia prevention; encourage family/friend attendance
- review use of glucagon
- consider revising A1C goal [2C]
- discuss and reinforce goals with patient
- adjust medications accordingly
- if insulin-treated, consider use of a more physiologic insulin replacement program [1C]
- consider and screen for other medical causes [1C]
- consider referral for blood glucose awareness training, if available [1B]
- consider use of continuous glucose monitoring (CGM)
- schedule follow-up appointment within 1-2 months. If history of recent, severe hypoglycemia or change in pattern of hypoglycemia, recommend increase in frequency of communicating blood glucose levels to provider or diabetes educator. [1B]

GLUCOSE MONITORING

Self-monitoring of blood glucose (SMBG) is an important component of the treatment program for all people with diabetes. Its use is to gauge treatment efficacy, help in treatment design, provide feedback on the impact of nutritional intake and activity, provide patterns that assist in medication selection, and for those on insulin, assist in daily dose adjustments. [1A]

Goals for glycemic control for people with diabetes are:

- Fasting glucose: 70-130 mg/dl
- 2-hour postprandial glucose: <180 mg/dl
- Bedtime glucose: 90-150 mg/dl

The frequency of SMBG is highly individualized and should be based on such factors as glucose goals, medication changes and patient motivation. Most patients with type 1 diabetes should monitor 4-6 times per day. Some patients may need to monitor even more frequently. For patients with type 2 diabetes, the frequency of monitoring is dependent upon such factors as mode of treatment and level of glycemic control. [1C]

To obtain meaningful data for treatment decisions, it is helpful for the patient to monitor for several consecutive days (e.g., 2-4 days). In addition to obtaining fasting and preprandial glucose levels, consider obtaining glucose readings 2-3 hours postprandially, as postprandial
Hyperglycemia has been implicated as an additional cardiovascular risk factor. [1C]

Postprandial monitoring is particularly recommended for patients who:
- have an elevated A1C but fasting glucose is at target
- are initiating intensive (physiologic) insulin treatment programs
- are experiencing problems with glycemic control
- are using glucose-lowering agents targeted at postprandial glucose levels
- are making meal planning or activity adjustments

1-hour postprandial glucose monitoring should be considered:
- during pregnancy
- for those patients using alpha-glucosidase inhibitors

Encourage the patient to bring SMBG results (written records or meter for downloading) to each visit for review with provider/educator.

Alternate Site Monitoring:
Blood glucose levels from sites such as the upper arm, forearm, and thigh may lag behind samples taken from the fingertips particularly when glucose levels are changing rapidly. Glucose levels may change rapidly with exercise, eating, after insulin administration or with hypoglycemia. For this reason, alternate site testing is not recommended in the following situations:
- when the blood glucose may be changing rapidly
- for patients using intensive insulin treatment programs
- if hypoglycemia is suspected
- in patients with hypoglycemia unawareness

HYPOGLYCEMIA

Prompt action is recommended for the treatment of hypoglycemia. When possible, the patient should confirm symptoms with SMBG to document hypoglycemia. All patients with type 1 diabetes should ensure that a family member/companion/caregiver knows how to administer a glucagon injection in the event the patient is unable or unwilling to take carbohydrate orally. [1C]

Treatment:
- Treat as mild-moderate hypoglycemia if patient is symptomatic or unable to confirm hypoglycemia with SMBG, or if blood glucose levels are >50 mg/dl and <70 mg/dl (<90 mg/dl at bedtime or overnight).
- Caution patient to avoid alternate site monitoring with blood glucose meter when hypoglycemic.
- For mild to moderate hypoglycemia (plasma glucose 51-70 mg/dl most times of the day and <90 mg/dl bedtime or overnight), begin with 15-20 grams carbohydrate (1/2 cup juice or regular soft drink, 3-4 glucose tabs, or 8-10 hard candies). [1C]

- If glucose level is ≤50 mg/dl, consume 20-30 grams carbohydrate. [1C]
- Recheck blood glucose after 15 minutes. [1B]
- Repeat hypoglycemia treatment if blood glucose does not return to normal range after 15 minutes. [1C]
- Follow with additional carbohydrate or snack if next meal is more than one hour away. [1C]
- If hypoglycemia persists after second treatment, patient or companion should be instructed to contact healthcare provider.
- In event of severe hypoglycemia (altered consciousness, unable to take carbohydrate orally, or requiring the assistance of another person) treat with glucagon and/or intravenous glucose. [1C]
- For patients with hypoglycemia unawareness, the threshold for treatment of hypoglycemia needs to be individualized. [2C]
- For patients using real-time CGM, check 15 minutes post treatment using a finger stick and not the sensor reading. Due to the physiologic lag between blood and interstitial glucose, the sensor will yield a lower result and can lead to over-treatment.

Education:
- Instruct patient to obtain and wear or carry diabetes identification.
- Inform patient of need to check blood glucose before driving, periodically during a long drive, and when operating heavy machinery. [1B]
- Instruct patient to carry treatment for hypoglycemia at all times.
- Identify possible causes of hypoglycemia in order to prevent it. [1C]
- Be clear in communicating modified treatment goals in individuals with hypoglycemia unawareness (see section in guideline on Hypoglycemia Unawareness). [1C]

DIABETES SELF-MANAGEMENT EDUCATION (DSME) and MEDICAL NUTRITION THERAPY (MNT)

Individuals with newly diagnosed diabetes should receive:
- DSME according to National Standards for Diabetes Self-Management Education [1A]
- individualized Medical Nutrition Therapy (MNT) [1A]
- multiple visits with diabetes educator (DE) to evaluate progress towards goals [1A]

Individuals with existing diabetes should receive:
- an annual assessment of the need for DSME and MNT, and referral, as appropriate, to a trained DE [2B]
- initial and ongoing assessment of psychosocial issues [1C]
PHYSICAL ACTIVITY

Guidelines for healthy adults:

- Physical activity should be an integral component of the diabetes care plan to optimize glucose control, decrease cardiovascular risk factors, and achieve or maintain optimal body weight. [1B]
- A moderate-intensity aerobic (endurance) physical activity minimum of 30 minutes (min) 5 days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min 3 days per week should be achieved unless contraindicated. Activity can be accumulated toward the 30-min minimum by performing bouts each lasting 10 or more minutes.
- A target of 60-90 minutes, 6-7 days per week is encouraged for weight loss if overweight or obese. [1B]
- To increase lean body mass, resistance training should be incorporated into the activity plan 3-4 days per week, and include upper, core and lower body strengthening exercises using free weights, resistance machines or resistance bands.
- Stretching exercises should be done when muscles are warm or at the end of the activity plan to loosen muscles and prevent soreness. [1B]

Guidelines for adults with medical or physical limitations:

- A moderate-intensity aerobic (endurance) physical activity minimum of 30 min 5 days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min 3 days per week should be achieved, as feasible, unless contraindicated. Activity can be accumulated toward the 30-min minimum by performing bouts each lasting 10 or more minutes.
- To increase lean body mass, resistance training should be incorporated into the activity plan 3-4 days per week, as feasible, and include upper, core and lower body strengthening exercises using free weights, resistance machines or resistance bands.
- Incorporate balance exercises to prevent falling and injury.
- All adults should consult their healthcare provider and/or see an exercise physiologist to discuss a safe exercise program that is appropriate to their abilities.

CARDIOVASCULAR HEALTH
(Also see sections on Lipids, Blood Pressure, Physical Activity and Smoking)

Treatment:
A daily enteric-coated ASA (75-162 mg) unless contraindicated * as a primary prevention strategy for men ≥50 years of age [2B] and for women ≥60 years of age [2B] with ONE or more of the following risk factors:
- Family history of premature** CAD or stroke
- HTN
- Current cigarette smoker
- Micro/macro albuminuria

- Hyperlipidemia

Recommend a daily enteric-coated ASA (75-162 mg) or clopidogrel (75 mg, if aspirin intolerant) or another agent of the class, as a secondary prevention strategy for anyone with ONE or more of the following: [1A]
- History of MI, angina, or documented CAD
- Vascular revascularization
- Non-hemorrhagic stroke
- TIA
- PAD

*Possible contraindications for antiplatelet therapy may include allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding and clinically active hepatic disease. Eye disease is usually not a contraindication for ASA therapy.

**Premature – 1st degree male relatives younger than 55; 1st degree female relatives younger than 65

Consider using beta-blocker in all patients with a history of MI or with documented CAD unless contraindicated. [1A]

Consider recommending aerobic exercise if not clinically contraindicated and a weight-loss program if patient is overweight or obese. [1A]

Consider using ACE inhibitors (or ARBs if ACE inhibitors not tolerated) in patients with known CAD or cardiovascular risk factors and age 55 or greater. [1A]

Thiazolidinediones (pioglitazone, rosiglitazone) are contraindicated in patients with NYHA classes III and IV and conditions of fluid overload (i.e., CHF).

Meta-analyses of clinical studies showed rosiglitazone to be associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction. Other studies comparing rosiglitazone to some other approved oral antidiabetic agents or placebo have not confirmed or excluded this risk. In the only long-term, randomized clinical trial (RECORD), there was no significant increase in the risk of cardiovascular events with rosiglitazone.

Indications for conducting a stress test:
Based on current research and understanding of coronary artery disease in diabetes, it is reasonable to screen patients with diabetes who: [1C]
- complain of typical or atypical chest pain
- have an abnormal ECG
- have a diagnosis of peripheral artery disease (PAD) or carotid disease
- are ≥35 years of age with sedentary lifestyle about to start a rigorous exercise program.

There is currently no strong evidence to support screening asymptomatic patients with type 2 diabetes for silent myocardial ischemia. [2B]
Patients with autonomic neuropathy may have increased risk of asymptomatic ischemia and therefore warrant careful attention. [1B]

If stress testing is performed, either rMPI or echocardiography with ECG monitoring is recommended. Exercise stress is preferred, if resting ECG is normal and patient is able to exercise, as the response to exercise is an important prognostic factor. If the patient cannot adequately exercise, pharmacologic stress testing is warranted.

LIPIDS

Screen:
Adults should be screened annually for lipid disorders with measurements of serum cholesterol, triglycerides, and LDL and HDL cholesterol, preferably fasting. [1C]

Lipid Goals: (mg/dl)
**LDL-Cholesterol (LDL-C):**
- <100 if no diagnosed CVD [1A];
- <70 if diagnosed CVD [1B]

**HDL-Cholesterol (HDL-C):**
- >40 (men); >50 (women) [2C]

**Triglycerides:** <150 (fasting) [2C]

Treatment:
All patients should receive information about a meal plan designed to lower blood glucose and improve lipids, physical activity recommendations, and risk reduction strategies. Consultation with appropriate education discipline is preferred. [1A]

Institute therapy after abnormal values are confirmed.

For patients in whom CVD is not yet diagnosed:

**If LDL-C ≥100 mg/dl:**
- optimize glycemic control [1A]
- refer to RD for intensive dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist or DE for exercise prescription
- recheck lipids within 6 weeks
- if LDL-C remains >100, if age 40 yrs of age and above [1A], or if age <40 yrs of age and multiple risk-factors [2C], initiate medication with goal of lowering LDL-C to <100, preferably with a statin, or by ~30-40% if goal not achieved by maximally tolerated statin therapy

**If LDL-C <100 mg/dl:**
Consider statin therapy if age >40 yrs and one more CVD risk factor is present (hypertension, smoking, albuminuria or family history of premature CVD). [1A]

Patients with cardiovascular disease (CVD):
**If LDL-C ≥ 70 mg/dl:**
- optimize glycemic control [1A]
- refer to RD for intensive dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist or DE for exercise prescription [1A]
- consider starting lipid lowering agent (preferably statin) immediately if LDL-C is >100 [1A]
- recheck lipids within 6 weeks
- if LDL-C remains >70, initiate/titrate medication (preferably a statin) with goal of lowering LDL-C to <70, or by ~ 30-40% if goal not achieved by maximally tolerated statin therapy [1A]. May require combination of a statin with another lipid lowering agent to achieve this goal. [1B]

Consider bile acid sequestrant or cholesterol absorption inhibitors or niacin (alone, or in combination therapy) for patients with statin intolerance or unacceptable adverse event.

**Patients with LDL-C at goal and fasting triglycerides ≥150 mg/dl or HDL-C ≤40 mg/dl:**
- optimize glycemic control [1A]
- refer to RD for dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist for exercise prescription
- recheck lipids within 6 weeks
- in patients with fasting triglyceride levels 200-499 mg/dl, calculate non-HDL-C (total cholesterol minus HDL-C) and consider starting or titrating statin if non-HDL-C >130 [1C]
- consider adding fibrate or niacin if fasting triglycerides >200 and/or HDL-C ≤40 mg/dl after non-HDL-C goal is met [2C]
- if triglycerides >500 mg/dl, initiate treatment with very low fat diet and fibrate for prophylaxis against acute pancreatitis; rule-out other secondary causes; reassess lipid status when triglycerides <500 mg/dl
- if fasting triglycerides remain >500 mg/dl after initiation of fibrate and /or niacin, consider the addition of fish oil (to provide 2-4 g omega-3 fatty acids daily)

BLOOD PRESSURE

Screen:
- Check BP at all routine visits after patient has sat for 5 minutes. Use proper-sized cuff and arm position. Postural BP should be checked initially, and as clinically indicated, and if orthostatic (defined as a fall in SBP of 20-30 mmHg or DBP of 10-15 mmHg or greater upon change in position) check at each follow-up visit. [1C]
- Consider initiating pharmacologic therapy if initial blood pressure is 140/90 and is confirmed by a subsequent measurement.
Goal:
- BP goal for each patient >18 years of age is <130/80 mmHg and modified for comorbidities. [1B]
- BP goal for patients with proteinuria >1 g is <125/75 mmHg. [1C]
- Initial goal for patients with isolated systolic HTN (SBP >180 mmHg and DBP <80 mmHg) is a SBP <160 mmHg.
- Initial goal for patients with SBP 160-179 mmHg is to lower SBP by 20 mmHg. If well tolerated, lower BP goals may be indicated. [1B]
- No clear evidence exists for significant benefits to be gained by lowering SBP to <140 mmHg in those with CHD or multiple risk factors. [1B]

Treatment: (If patient smokes)
- Discuss rationale for and strongly recommend smoking cessation. [1A]
- Review options available to assist in smoking cessation, including medications and cessation programs. [1B]

RENAL DISEASE AND MICRO-MACRO ALBUMINURIA

Screen:
Measure serum creatinine at least annually to estimate glomerular filtration rate (GFR) regardless of degree of urine albumin excretion. (See Joslin’s Guideline for Specialty Consultation/Referral for guidance as to when to refer to a renal specialist.) [1C]

If eGFR is <60 ml/min, evaluate for complications of kidney disease (anemia, hyperparathyroidism, and vitamin D deficiency).

Screen for micro/macro albuminuria by checking urine albumin/creatinine (A/C) ratio as follows:
- type 1 patients within 5 years after diagnosis and then yearly [1C]
- type 2 patients at diagnosis (after glucose has been stabilized) and then yearly [1C]
- annually in all patients up to age 70 years [2C]
- as clinically indicated in patients >70 years of age

Micro/macro albuminuria is recognized as a major independent risk factor for CAD in patients with diabetes. Albuminuria may be measured with a spot or timed urine collection. Spot urine is preferred for simplicity.

Continue use of routine urinalysis as clinically indicated. [2C]

Drug therapy:
Efficaciousness is the most important consideration in choosing an initial anti-hypertensive drug. In that sense, any available antihypertensive drug can be an appropriate choice; however, other considerations (presence of proteinuria, co-existing CAD, or cost) dictate a preference for ACE inhibitors, ARBs, beta-blockers and diuretics. [1A]

ACE inhibitors or ARBs are the drugs of choice, after achieving A1C and blood pressure goals, for patients with urine albumin >30 mcg/mg. These drugs require monitoring of serum creatinine and K⁺ within 1-2 weeks of starting therapy and periodically thereafter. [1A] (See section on Renal Disease and Micro-Macro Albuminuria)

SMOKING

Screen:
- Assess patient’s smoking status on a routine basis.
• consider consult with nephrologist for blood pressure control, successive increases in microalbumin and other issues (i.e., GFR <60 ml/min) [2C]

Once confirmed:
• evaluate BP and initiate/modify aggressive blood pressure treatment to achieve a BP of <130/80 mmHg [1A]
• recommend patient self-monitor BP with portable cuff and maintain a record/log. The monitoring schedule should be determined with the healthcare provider and is based on patient circumstance.
• strive to improve glycemic control with an optimal goal A1C of <7% or as otherwise clinically indicated [1A]
• refer to diabetes educator for glucose management
• initiate/ modify ACE inhibitor or ARB treatment if microalbuminuria persists. Check K+ and creatinine 1-2 weeks after making changes. [1A]
• repeat A/C ratio at least every 6 months. Consider increase in frequency when changes in medication are made. [2C]

If A/C ratio > 300 mcg/mg (> 300 mg/24 hr) or proteinuria (positive dipstick for protein or ≥30 mg/dl):
• follow all guidelines as stated for A/C ratio 30-300 mcg/mg
• consider BP goal of <125/75 mmHg [2B]
• consult with nephrologist if: [1C]
  ○ rapid rise in serum creatinine, abnormal sediment, or sudden increase in proteinuria
  ○ need to refine treatment program to prevent further deterioration
  ○ problems with ACE inhibitors, difficulties in management of high BP, or hyperkalemia
  ○ etiology of nephropathy is questionable
  ○ management of hyperphosphatemia presents difficulties
  ○ anemia due to renal disease
• consider reducing protein in the diet [1B]
• consider nutrition referral

EYES

Exam Schedule:
Refer patient for comprehensive dilated eye exam or validated retinal imaging to determine level of retinopathy.
• Type 1: initial eye exam within 3 years after diagnosis of diabetes once patient is 9 years of age or older and annually thereafter. [1B]
• Type 2: at diagnosis and annually thereafter [1B]
• Pregnancy in pre-existing diabetes: prior to conception and during first trimester with follow-up as determined by first trimester exam and 6-12 weeks post partum. [1B]
For physiologic insulin therapy (pump therapy or multiple daily injections): consult with patient’s eye doctor or evaluate retinal status with validated retinal imaging to determine level of retinopathy and appropriate follow-up care prior to initiating physiologic insulin therapy.

Treatment:
Aggressively treat known medical risk factors for retinopathy: [1A]
• Strive to improve glycemic control with optimal A1C goal of <7%.
• Monitor eye disease carefully when intensifying glycemic control.
• Strive for BP <130/80 mmHg.
• Treat micro/macro albuminuria.
• Strive to maintain total cholesterol, LDL, HDL and triglyceride levels as per the recommendations outlined in the Lipids Section of this Guideline.
• Treat anemia.

Revise activity program depending on the level of retinopathy.

Reinforce follow-up with eye care provider for any level of retinopathy including no apparent retinopathy. The frequency of follow-up is dependent upon the level of retinopathy and is determined by the eye care provider.
• For high-risk proliferative diabetic retinopathy, scatter (panretinal) photocoagulation is indicated promptly. [1A]
• For clinically significant macular edema (CSME), focal laser and/or intravitreal ranibizumab injection is generally indicated regardless of level of retinopathy. [1A]
• The level of diabetic retinopathy and diabetic macular edema (DME) generally determines follow-up.* [1A]

If No Diabetic Retinopathy:
12 months

If Mild Nonproliferative Diabetic Retinopathy:
Without DME  12 months
With DME**  3-4 months

If Moderate Nonproliferative Diabetic Retinopathy:
Without DME  6-9 months
With DME**  3-4 months

If Severe - Very Severe Nonproliferative Diabetic Retinopathy:
Without DME***  3-4 months
With DME**  3-4 months

If Proliferative Diabetic Retinopathy less than High-Risk:
Without DME**  1 week – 3-4 months
With DME**  1 week – 3-4 months

If High-Risk Proliferative Diabetic Retinopathy
With or without DME – scatter laser surgery with follow-up in 3 months
The presence of known risk factors for onset and progression of retinopathy may suggest follow-up at shorter intervals for all levels of retinopathy.

** Focal laser surgery and/or intravitreal ranibizumab injection is generally indicated for CSME. If receiving intravitreal ranibizumab injection, follow-up may be as frequent as monthly.

*** Scatter laser surgery may be indicated, especially for type 2 diabetes or type 1 diabetes of long duration.

Intravitreal injections of steroids and ant-VEGF agents other than ranibizumab, are sometimes used in clinical practice to treat macular edema despite limited studies on their effectiveness or safety to date. These modalities are currently under rigorous investigation to further define their role.

**PERIPHERAL NEUROPATHY**

**Screen:**
- Ask patient about loss of sensation in the limbs, symptoms of pain, tingling, paresthesia, weakness or gait instability.
- Evaluate feet for sensation and reflexes.
- Laboratory screening with complete blood count, lipid panel, thyroid panel, B12 level (with methylmalonic acid +/- homocysteine), serum and urine protein electrophoresis, as clinically indicated.
- Neurophysiologic testing (EMG, quantitative sensory testing) should be considered in atypical cases.
- Assess for symptoms of autonomic neuropathy such as erectile dysfunction, gastroparesis, or postural hypotension.

**Frequency:**
- For patients with type 1 and 2 diabetes without complications, conduct symptom and examination screen at time of diagnosis and at least annually. [1C]
- For the “at-risk patients,”* conduct symptom and examination screen at all routine interval visits. [1C]
- Laboratory screening at the time of diagnosis of diabetes or with change in symptoms or examination. [1C]
- Screening for cardiovascular autonomic neuropathy at the time of diagnosis of type 2 diabetes, or 5 years after diagnosis of type 1 diabetes. Screening should be repeated yearly or with development of symptoms. [1C]
- Neurophysiologic testing only for atypical cases. [1C]

***“At-Risk Patients”*** include patients who smoke, have vascular insufficiency, neuropathy, retinopathy, nephropathy, history of ulcers or amputations, structural deformities, infections, skin/nail abnormality, are on anticoagulation therapy or who cannot see, feel or reach their feet.

---

**Treatment:**

*For patients with acute problems or who are “at risk”:*
- Consider referral to neurologist for:
  - atypical neuropathy
  - rapidly progressive symptoms
  - severe pain unresponsive to first line therapy
  - weakness suggestive of diabetic amyotrophy

*For patients with symptoms related to diabetic peripheral or autonomic neuropathy:*
- Consider medications as they improve quality of life [1A]

**FEET**

**Screen:**
- Screening should include:
  - questions about loss of sensation in the limbs, or symptoms of pain, tingling or other paresthesia
  - foot evaluation for sensorimotor (monofilament), skin and soft tissue integrity, nail condition, vascular sufficiency (pedal pulses) and biomechanical integrity
  - examination of shoes for wear

**Frequency:**
- For patients with type 1 and 2 diabetes without complications, conduct foot screen at time of diagnosis and at least annually thereafter. [1C]
- For the “at-risk patients,”* check feet at all routine interval visits. [1C]

***“At-Risk Patients”*** include patients who smoke, have vascular insufficiency, neuropathy, retinopathy, nephropathy, history of ulcers or amputations, structural deformities, infections, skin/nail abnormality, are on anticoagulation therapy or who cannot see, feel or reach their feet.

**Treatment:**

*For patients with acute problems or who are “at risk”:*
- refer to podiatrist for routine care and evaluation [1B]
- refer to DE for foot care training* [1C]
- consider referral to neurologist for:
  - atypical neuropathy
  - rapidly progressive symptoms
  - severe pain unresponsive to first line therapy
  - weakness suggestive of diabetic amyotrophy

*Foot care training:*
- Foot care training should address:
  - avoidance of foot trauma
  - daily foot inspection
  - nail care
  - proper footwear
  - impact of loss of protective sensation on morbidity
  - need for smoking cessation
  - action to take when problems arise
  - importance of glucose control on disease progression
**For current ulcer or infection: mild** [1C]

**Mild Infection or Ulcer**
- Superficial (no foul odor)
- No bone or joint involvement
- Minimal or no cellulitis (< 2 cm)
- Instruct patient in non-weight bearing, if appropriate
- Apply local dressings
- Consider baseline x-ray to evaluate for bone integrity and possible osteomyelitis
- Consider systemic antibiotic therapy
- Refer to podiatrist for debridement or further treatment
- Ensure follow-up appointments are kept

**For limb-threatening*** ulcer or infection: [1C]

***Limb-threatening***
- Deep ulcer
- Gangrene
- >2 cm cellulitis
- Significant ischemia
- Immunocompromised
- Osteomyelitis, presumed to be present if probed to the bone.
- Consider hospitalization
- Refer to a podiatrist and vascular surgeon for immediate evaluation and treatment

**For current ulcer or infection: mild** [1C]

**Mild Infection or Ulcer**
- Superficial (no foul odor)
- No significant ischemia
- No bone or joint involvement
- No systemic toxicity
- Minimal or no cellulitis (< 2 cm)
- Instruct patient in non-weight bearing, if appropriate
- Apply local dressings
- Consider baseline x-ray to evaluate for bone integrity and possible osteomyelitis
- Consider systemic antibiotic therapy
- Refer to podiatrist for debridement or further treatment
- Consider baseline x-ray to evaluate for bone integrity and possible osteomyelitis
- Refer to foot care training
- Ensure follow-up appointments are kept

**Mental Health**

A psychosocial evaluation should be an integrated component of the initial assessment and the ongoing care of all patients with diabetes and should be strongly considered in the following situations:

**Newly diagnosed diabetes:**
Assess at least the following:
- Ability to cope with the emotional impact and lifestyle changes of diabetes
- Level of social support
- Type and degree of non-diabetes related stress

**Newly diagnosed complications from diabetes:**
Assess at least the following:
- Ability to cope with the emotional impact and lifestyle changes
- Level of social support
- Type and quantity of non-diabetes related stress

**When changes in treatment, self-care, or metabolic stability as evidenced by:**
- Diabetes burnout or lack of adherence with treatment regimen: consider using PAID as a screening tool.
- Symptoms of depression: consider using PHQ-9 or PHQ-2 as a screening tool.
- Symptoms of anxiety (e.g., compulsive SMBG)
- A1C >10% and inquiry indicates insulin mismanagement by the patient (omission or under-dosing)
- Exaggerated fear of hypoglycemia
- Recurrent DKA
- Family conflict related to diabetes
- Substance abuse: consider use of CAGE alcohol screening tool

**IMMUNIZATIONS**

Recommend the following vaccines:
- Influenza vaccine: yearly for all adult patients with diabetes [1B]
- Pneumococcal vaccine: once for all patients with diabetes. [1B]
  - Patients ≥ 65 years of age should receive a second dose of pneumococcal vaccine if they received the previous dose ≥ 5 years earlier and they were < 65 years of age when they received the previous dose.
- Consider vaccines for other disease prevention such as for herpes zoster

**Women's Health**

(Refer to Joslin’s Guideline for Detection and Management of Diabetes in Pregnancy for more details)

- Counsel women with the potential for conception about contraception use and relationship of blood glucose control to fetal development and pregnancy outcomes. [1C]
- At initial and annual visit, discuss sexual function.
  - Assess for infectious, hormonal, psychological, or structural etiologies if dysfunction exists.
  - Refer to specialist as indicated. [1C]
- Follow appropriate guidelines for pap/pelvic and mammography screening for primary care patients. [1A]
- Individualize approach to bone health for women with risk factors for osteoporosis, including surgical and natural menopause. [1B]
  - Ensure adequate intake of calcium and vitamin D.

**Men's Health**

- At initial and annual visit, discuss sexual function.
- Assess for hormonal, psychological, or structural etiologies if dysfunction exists. [1C]
- For men with type 2 diabetes, consider screening for low testosterone:
  - Screen with total testosterone, and sex hormone binding globulin
- Refer to specialist as indicated.
DENTAL CARE

• Periodontal disease is associated with suboptimal diabetes control and may be a risk factor for cardiovascular disease.
• At initial visit and annually, discuss need for dental exams at least every six months.

• If evidence of gingivitis, may need dental evaluation/treatment every 3-4 months.
• Refer to dental specialist for oral symptoms such as sore, swollen, or bleeding gums, loose teeth or persistent mouth ulcers. [1C]
List of Abbreviations

AACE - American Association of Clinical Endocrinologists
A1C - glycohemoglobin (hemoglobin A1c)
A/C Ratio - albumin/creatinine ratio
ACE inhibitor - angiotensin-converting enzyme inhibitor
ADA - American Diabetes Association
ADAG - A1c-Derived Average Glucose study
ARBs - angiotensin receptor blockers
ASA - aspirin
BP - blood pressure
CAD - coronary artery disease
CAGE - Alcohol screening questionnaire
CGM - Continuous glucose monitoring
CHF - Congestive heart failure
CSME - clinically significant macular edema
CVD - cardiovascular disease
CVD - cardiovascular disease, including coronary heart disease, peripheral vascular disease, and cerebrovascular disease
DBP - diastolic blood pressure
DCCT - Diabetes Control and Complication Trial
DE - diabetes educator
DKA - diabetic ketoacidosis
DME - diabetic macular edema
DSME - diabetes self-management education
eAG - estimated average blood glucose
ECG - electrocardiogram
eGFR - estimated glomerular filtration rate
EMG - electromyogram
GFR - glomerular filtration rate
GRADE - Grading of Recommendations, Assessment, Development and Evaluation
HDL-C - high-density lipoprotein cholesterol
HTN - hypertension
IDF - International Diabetes Federation
K+ - potassium
LDL-C - low-density lipoprotein cholesterol
MDRD - Modification of diet in renal disease study equation
http://nkdep.nih.gov/professionals/gfr_calculators/orig_con.htm
MI - myocardial infarction
Min - minutes
MNT - medical nutrition therapy
NGSP - National Glycohemoglobin Standardization Program
NYHA - New York Heart Association
PAD - peripheral arterv disease
PAID - Problem Areas in Diabetes
PHQ-2 - Patient Health Questionnaire 2 questions
PHQ-9 - Patient Health Questionnaire, 9 questions
PVD - peripheral vascular disease
RD - registered dietitian
RECORD study - Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
rMPI - radionuclide myocardial perfusion imaging
SBP - systolic blood pressure
SMBG - self-monitoring of blood glucose
TIA - transient ischemic attack
TLC - therapeutic lifestyle changes
UTI - urinary tract infection
VEGF- vascular endothelial growth factor

Approved by the Joslin Clinical Oversight Committee on 05/20/2010

The Joslin Clinical Oversight Committee gratefully acknowledges: Elena Savoia, MD, MPH, Acting Director, Center for Public Health Preparedness, Harvard School of Public Health, Boston, in the supervision of the grading process and Peter Polewski, graduate student, for his assistance with the literature search and review.
<table>
<thead>
<tr>
<th>Joslin Clinical Oversight Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Om Ganda, MD - Chairperson</td>
</tr>
<tr>
<td>Richard Beaser, MD</td>
</tr>
<tr>
<td>Elizabeth Blair, MS, ANP-BC, CDE</td>
</tr>
<tr>
<td>Amy Campbell, MS, RD, CDE</td>
</tr>
<tr>
<td>Cathy Carver, ANP-BC, CDE</td>
</tr>
<tr>
<td>Jerry Cavallerano, OD, PhD</td>
</tr>
<tr>
<td>David Feinbloom, MD</td>
</tr>
<tr>
<td>Richard Jackson, MD</td>
</tr>
<tr>
<td>Lori Laffel, MD, MPH</td>
</tr>
<tr>
<td>Melinda Maryniuk, MEd, RD, CDE</td>
</tr>
</tbody>
</table>
### Grading System Used in Guideline

<table>
<thead>
<tr>
<th>Grade of Recommendation</th>
<th>Clarity of risk/benefit</th>
<th>Quality of supporting evidence</th>
</tr>
</thead>
</table>
| **1A** Strong recommendation  
High quality of evidence | Benefits clearly outweigh risk and vice versa. | Consistent evidence from well performed randomized, controlled trails or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. |
| **1B** Strong recommendation  
Moderate quality of evidence | Benefits clearly outweigh risk and burdens, or vice versa. | Evidence from randomized, controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research is likely to have an impact on our confidence in the estimate of the benefit and risk and may change the estimate. |
| **1C** Strong recommendation  
Low quality of evidence | Benefits outweigh risk and burdens, or vice versa. | Evidence from observational studies, unsystematic clinical experience, or from randomized controlled trails with serious flaws. Any estimate of effect is uncertain. |
| **2A** Weak recommendation  
High quality of evidence | Benefits closely balanced with risks and burdens. | Consistent evidence from well performed randomized controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. |
| **2B** Weak recommendation  
Moderate quality of evidence | Benefits closely balanced with risks and burdens; some uncertainty in the estimates of benefits, risks and burdens. | Evidence from randomized controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate. |
| **2C** Weak recommendation  
Low quality of evidence | Uncertainty in the estimates of benefits, risks and burdens; benefits may be closely balanced with risks and burdens. | Evidence from observational studies, unsystematic clinical experience, or from randomized controlled trails with serious flaws. Any estimate of effect is uncertain. |

Evidence graded less than “A” is acceptable to support clinical recommendations in a guideline. It is also assumed that for many important clinical recommendations, it would be unlikely that level A evidence be obtained because appropriate studies may never be performed.